Medical/Pharmaceuticals
INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense
PLYMOUTH MEETING, Pa., Nov. 16, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that it has received clearance from the U.S. Food & Dru...
2020-11-16 20:00
3805
KPCPEN Introduces Two Paediatric Professors to Accelerate the Preparation of COVID-19 Vaccine
JAKARTA, Indonesia, Nov. 16, 2020 /PRNewswire/ -- The government through Covid-19 Handling and National Economic Recovery Committee (KPCPEN) continues its various efforts in handling the pandemic as well as bringing economic relief inIndonesia. In its efforts to progress the COVID-19 vaccine, ...
2020-11-16 16:46
2037
Gilead Sciences Announces Recipients of its First Asia HIV Research Scholar Program
HONG KONG, Nov. 16, 2020 /PRNewswire/ -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the recipients of its first Asia HIV Research Scholar Program ("Program"). The Program awards up toUS$130,000 over a period of two years to support innovative HIV scientific research led by early-career ...
2020-11-16 15:02
4156
Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate
* Clover aims to double its commercial manufacturing capacity in preparation for global Phase 2/3 trials * Cytiva provides FlexFactory™ bioprocessing upstream and downstream solutions for Clover to accelerate GMP facility development and shorten time to market SHANGHAI, Nov. 16, 2020 /PRNewsw...
2020-11-16 14:00
1608
Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 American Academy of Ophthalmology
SAN FRANCISCO and SUZHOU, China, Nov. 16, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2020-11-16 08:00
5633
CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN If approved by the European Commission, ELZONRIS will be the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, inEurope FLORENCE, Italy, Nov. 14...
2020-11-14 01:03
4318
FDI World Dental Federation: Study shows dramatic rise in antibiotics prescribed to dental patients in England during COVID-19 lockdown earlier this year
FDI World Dental Federation (FDI) releases new White Paper on antibiotic resistance to mark World Antimicrobial Awareness Week GENEVA and LONDON, Nov. 14, 2020 /PRNewswire/ -- One of the unintended consequences of the COVID-19 lockdowns inEngland earlier this year has been a 25 per cent increase...
2020-11-14 01:00
4106
The fourth CIIE begins taking stall reservations from exhibitors
SHANGHAI, Nov. 13, 2020 /PRNewswire/ -- Some exhibitors planning to attend the fourth China International Import Expo (CIIE) next year started to reserve their stalls onNov 8. This is the first time that the CIIE has offered such an option. Five dairy companies – Fonterra, Mille, Ausnutria, Yash...
2020-11-13 21:00
4166
AlpVision to offer free of charge security feature to protect COVID-19 relevant medicines against counterfeiting
VEVEY, Switzerland, Nov. 13, 2020 /PRNewswire/ -- On November 13th, 2020,
AlpVision is launching the "AlpVision COVID-19 Initiative" helping
pharmaceutical companies to protect COVID-19 relevant medicines against
counterfeiting.
2020-11-13 20:25
3142
Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer
STOCKHOLM, Nov. 13, 2020 /PRNewswire/ -- RhoVac announces today, November 13, 2020, that the results of its clinical phase I/II study have been published in the Journal for ImmunoTherapy of Cancer (JITC). The scientifically reviewed article reports that the treatment with RhoVac's drug candidate ...
2020-11-13 17:53
2319
iONEBIO Inc. Deployment of FICS (Fast Infection Control System) at the International Airport of Paraguay
* iONEBIO iLAMP Novel-CoV19 Detection Kit is a high-speed laboratory assay intended as a groundbreaking aid in the diagnosis of SARS-CoV-2 infection. * This technologically advanced solution was developed in an attempt to serve as the gold standard in high-throughput high-accuracy testing, wit...
2020-11-13 16:29
1887
iONEBIO Inc. Deployment of FICS (Fast Infection Control System) at the International Airport of Paraguay
* iONEBIO iLAMP Novel-CoV19 Detection Kit is a high-speed laboratory assay intended as a groundbreaking aid in the diagnosis of SARS-CoV-2 infection. * This technologically advanced solution was developed in an attempt to serve as the gold standard in high-throughput high-accuracy testing, wit...
2020-11-13 15:18
1847
Ascensia Diabetes Care Showcases The Crucial Support Nurses Provide People With Diabetes To Celebrate World Diabetes Day 2020
BASEL, Switzerland, Nov. 13, 2020 /PRNewswire/ -- Ascensia Diabetes Care, a leading global diabetes care company and maker of the CONTOUR® range of blood glucose monitoring systems, is tomorrow celebrating the crucial role that nurses play in helping people manage their diabetes, as part of World...
2020-11-13 14:00
2908
Integrating Fitbit Wearable Devices into Diabetes Care Leads to Significant Improvements in Blood Glucose and HbA1C, Finds Health2Sync Clinical Study in Taiwan
* Wearing Fitbit devices with Health2Sync glucose control app clinically proven to help both users and healthcare providers to control and better manage the symptoms of Type 2 diabetes * Results from the study in Taiwan revealed an improvement in patients' health conditions, with participants...
2020-11-13 11:07
2199
Integrating Fitbit Wearable Devices into Diabetes Care Leads to Significant Improvements in Blood Glucose and HbA1C, Finds Health2Sync Clinical Study in Taiwan
* Wearing Fitbit devices with Health2Sync glucose control app clinically proven to help both users and healthcare providers to control and better manage the symptoms of Type 2 diabetes * Results from the study in Taiwan revealed an improvement in patients' health conditions, with participants...
2020-11-13 10:34
1888
Integrating Fitbit Wearable Devices into Diabetes Care Leads to Significant Improvements in Blood Glucose and HbA1C, Finds Health2Sync Clinical Study in Taiwan
* Wearing Fitbit devices with Health2Sync glucose control app clinically proven to help both users and healthcare providers to control and better manage the symptoms of Type 2 diabetes * Results from the study in Taiwan revealed an improvement in patients' health conditions, with participants...
2020-11-13 10:32
2026
Integrating Fitbit Wearable Devices into Diabetes Care Leads to Significant Improvements in Blood Glucose and HbA1C, Finds Health2Sync Clinical Study in Taiwan
* Wearing Fitbit devices with Health2Sync glucose control app clinically proven to help both users and healthcare providers to control and better manage the symptoms of Type 2 diabetes * Results from the study in Taiwan revealed an improvement in patients' health conditions, with participants...
2020-11-13 10:29
1997
Integrating Fitbit Wearable Devices into Diabetes Care Leads to Significant Improvements in Blood Glucose and HbA1C, Finds Health2Sync Clinical Study in Taiwan
* Wearing Fitbit devices with Health2Sync glucose control app clinically proven to help both users and healthcare providers to control and better manage the symptoms of Type 2 diabetes * Results from the study in Taiwan revealed an improvement in patients' health conditions, with participants...
2020-11-13 10:26
2191
Molecular Stethoscope Announces Completion of its NAFLD/NASH Study and Podium Presentation of Results by Dr. Naga Chalasani at the AASLD Liver Meeting 2020
Study results demonstrate the utility of the company's Next-Generation cf-mRNA Liquid Biopsy-Artificial Intelligence Technology Platform for the characterization of NAFLD/NASH disease PALO ALTO, Calif., Nov. 13, 2020 /PRNewswire/ -- Molecular Stethoscope, Inc., a precision medicine biotechnology...
2020-11-13 04:19
2005
ZEISS presents integrated workflow advancements at AAO
The latest solutions from ZEISS help doctors advance ophthalmic care with new ways to maximize clinical efficiency and performance DUBLIN, Calif., Nov. 13, 2020 /PRNewswire/ -- The Medical Technology segment of ZEISS will present its latest integrated diagnostic and surgical advancements at th...
2020-11-13 04:15
1850
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116